CorVel Corporation — Form 10-Q Summary
Reporting period: The filing covers the three months ended June 30, 2018, CorVel’s fiscal 2019 first quarter, with comparison to the three months ended June 30, 2017. This differs from the request metadata period of 2017 Q1.
Business context and results
CorVel provides managed-care and medical cost-containment services, primarily for workers’ compensation, auto claims, and group health payors. It reports one operating segment. Revenue is generated by patient management and network solutions services.
| Metric | Q1 FY2019 | Q1 FY2018 | Change |
|---|---|---|---|
| Revenue | $150.4 million | $137.6 million | +9.3% |
| Gross profit | $31.4 million | $28.8 million | +8.9% |
| Gross margin | 20.8% | 20.9% | Down 0.1 percentage point |
| General and administrative expense | $15.9 million | $14.6 million | +8.9% |
| Income before taxes | $15.4 million | $14.2 million | +8.9% |
| Net income | $11.8 million | $8.8 million | +34.2% |
| Diluted EPS | $0.62 | $0.46 | +34.8% |
| Operating cash flow | $22.8 million | $21.4 million | +$1.4 million |
Financial position and liquidity
- Cash and cash equivalents were $73.3 million at June 30, 2018, up from $55.8 million at March 31, 2018. Working capital was $78.4 million, versus $65.3 million at fiscal year-end.
- There was no debt outstanding. A revolving credit facility provides up to $10 million; it expires in September 2018, and the company expects to renew it. The company reported compliance with its covenants.
- Operating cash flow was $22.8 million; capital expenditures were $3.0 million. The company used $2.3 million in financing activities, including $3.5 million for treasury-stock purchases and $1.2 million of option-exercise proceeds.
- Total assets were $291.2 million and total liabilities were $109.3 million at quarter-end. Contractual obligations included $63.6 million of operating lease payments and $1.6 million of uncertain tax positions.
Material changes and management commentary
- Patient management revenue rose 15.1% to $87.9 million, primarily from claims-management services, partly offset by lower case-management services. It represented 58.4% of revenue, up from 55.5%.
- Network solutions revenue increased 2.1% to $62.5 million; the number of bills reviewed increased 5.4% year over year.
- Cost of revenue rose 9.4%, broadly in line with revenue growth. Management cited increased field-operations headcount (164 employees) and pharmacy service costs. G&A increased due to legal expenses, corporate systems costs, and performance-based stock compensation.
- The effective tax rate fell to 23.6% from 38.0%, primarily reflecting the Tax Cuts and Jobs Act. Management expects an effective combined federal and state tax rate of approximately 24%–26% for fiscal 2019, subject to assumptions and tax-law interpretation.
- CorVel adopted ASC 606 on April 1, 2018 using the modified retrospective method; management reported no material effect on the quarter’s income-statement or balance-sheet line items. The company had $47.4 million of remaining performance obligations, of which approximately 82% was expected to be recognized within one year.
Outlook, risks, and contingencies
- Management said cash, expected internally generated funds, and the credit facility should cover expected requirements for at least 12 months, including operations, investment, and share repurchases. No specific revenue or earnings guidance was provided.
- Management identified potential pressure from declining workers’ compensation claims, competition and customer insourcing, pricing pressure, changes in customer demand and regulation, labor and benefit costs, and the ability to develop competitive software and grow TPA services.
- Other disclosed risks include data-security incidents or system interruptions, medical-management and other litigation exposure, dependence on key personnel, and uncertainty in interpreting the Tax Cuts and Jobs Act. Management said ordinary-course litigation was not expected to have a material financial effect.
- The company repurchased 66,553 shares for $3.5 million during the quarter at an average $52.38 per share. After quarter-end, it repurchased an additional 24,001 shares for $1.334 million, averaging $55.60 per share.
- The company is evaluating the impact of the new lease standard, effective for it April 1, 2019. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended comparison period: the filing is for the quarter ended June 30, 2018, not 2017 Q1 as stated in the request metadata.
- Assess whether patient-management growth, particularly claims-management growth, can continue and whether it offsets weaker case-management activity and broader claims-volume risks.
- Track gross-margin trends, staffing and pharmacy costs, and the effect of increased legal, systems, and stock-compensation expenses.
- Verify the expected tax-rate range as tax guidance evolves, and monitor cash generation, working-capital movements, and share repurchases.
- Confirm renewal of the $10 million credit facility and assess lease commitments, litigation, and other disclosed operational and regulatory risks.